Plasma Level Monitoring for Maintenance Neuroleptic Therapy

  • S. R. Marder
  • T. Van Putten
  • M. Aravagiri
Part of the Psychopharmacology Series book series (PSYCHOPHARM, volume 7)


Schizophrenic patients differ markedly in the dose of neuroleptic that is necessary to treat their acute exacerbations of illness and to maintain their remissions once they have been adequately treated. Decisions about drug dosage during the maintenance phase are particularly problematic because the clinician is unable to assess a clinical response in individuals who are clinically stable. During this phase, the monitoring of plasma levels of neuroleptic drugs could provide an objective method of assessing a patient’s pharmacotherapy. Unfortunately, there have been very few studies of plasma level measurement in maintenance therapy. However, the available studies (Brown et al. 1982; Wistedt et al. 1982) suggest that patients with lower plasma levels are more vulnerable to relapse.


Maintenance Therapy Schizophrenic Patient Haloperidol Decanoate Depot Drug Fluphenazine Decanoate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Brown WA, Laughren T, Chisholm E, Williams BW (1982) Low serum neuroleptic levels predict relapse in schizophrenic patients. Arch Gen Psychiatry 39: 998–1000PubMedGoogle Scholar
  2. Cohen BM, Waternaux C, Chouinard G, Sommer BR, Jones B (1985) Plasma levels of neuroleptic in patients receiving depot fluphenazine. J Clin Psychopharmacol 5: 328–332PubMedGoogle Scholar
  3. Dahl SG (1976) Pharmacokinetics of methotrimeprazine after single and multiple doses. ClinGoogle Scholar
  4. Pharmacol Ther 19:435–442Google Scholar
  5. Dahl SG, Strandjord RE (1977) Pharmacokinetics of chlorpromazine after single and chronic dosage. Clin Pharmacol Ther 21: 409–414Google Scholar
  6. Deberdt R, Elens W, Berghmans J, Heykants R, Woesterborghs R, Driesens F, Reyntjens A, van Wijngaarden I (1980) Intramuscular haloperidol decanoate for neuroleptic maintenance therapy: efficacy, dosage schedule, and plasma levels. Acta Psychiatr Scand 62: 356–363PubMedCrossRefGoogle Scholar
  7. De Buck RP, Zelaschi N, Gilles C, Durdu J, Brauman H (1981) Theoretical and practical importance of plasma levels of haloperidol. Correlations with clinical and computerized EEG data. Prog Neuro Psychopharmacol 5: 499–502CrossRefGoogle Scholar
  8. De Cuyper H, Bollen J, van Praag HM, Verstraeten D (1986) Pharmacokinetics and therapeutic efficacy of haloperidol decanoate after loading dose administration. Br J Psychiatry 148: 560–566PubMedCrossRefGoogle Scholar
  9. Dudley J, Rauw G, Hawes EM, et al. (1983) Correlation of fluphenazine plasma levels versus clinical response in patients: a pilot study. Prog Neuro Psychopharmacol Biol Psychiatry 7: 791–795CrossRefGoogle Scholar
  10. Dysken MW, Javaid JI, Chang SS, Schaffer C, Shahid A, Davis JM (1981) Fluphenazine pharmacokinetics and therapeutic response. Psychopharmacology (Berlin) 73: 205–210CrossRefGoogle Scholar
  11. Freeman H (1980) Twelve years’ experience with the total use of depot neuroleptics in a defined population. In: Cattabeni F et al. (eds) Long-term effects of neuroleptics. Raven, New York, pp 559–564Google Scholar
  12. Gelders YG (1986) Pharmacology, pharmacokinetics and clinical development of haloperidol decanoate. Int Clin Psychopharmacol 1(s):l–l1Google Scholar
  13. Hartmann F, Gruenke LD, Craig JC, Bissell DM (1983) Chlorpromazine metabolism in extracts of liver and small intestine from guinea pig and from man. Drug Metab Dispos 11: 244–248PubMedGoogle Scholar
  14. Marder SR, Hawes EM, van Putten T, Hubbard JW, McKay G, Mintz J, May PRA, Midha KK (1986) Fluphenazine plasma levels in patients receiving low and conventional doses of fluphenazine decanoate. Psychopharmacology (Berlin) 88: 480–483CrossRefGoogle Scholar
  15. Marder SR, van Putten T, Mintz J, Lebeil M, McKenzie J, May PRA (1987) Low and conventional dose maintenance therapy with fluphenazine decanoate: two year outcome. Arch Gen Psychiatry 44: 518–521PubMedGoogle Scholar
  16. Mavroidis ML, Kanter DR, Hirschowitz J, Garver DL (1984) Fluphenazine plasma levels and clinical response. J Clin Psychiatry 45: 370–373PubMedGoogle Scholar
  17. McCreadie RG, McKane JP, Robinson ADT, Wiles DH, Stirling GS (1986) Depot neuroleptics as maintenance therapy in chronic schizophrenic inpatients. Int Clin Psychopharmacol 1 (s): 13–14Google Scholar
  18. Midha KK, Hubbard JW, Marder SR, Hawes EM, van Putten T, McKay G, May PRA (1987) The sulfoxidation of fluphenazine in schizophrenic patients maintained on fluphenazine decanoate. Psychopharmacology (Berlin) 93: 369–373CrossRefGoogle Scholar
  19. Reyntjens AJM, Heykants JJP, Woestenborghs RJH, Gelders YG, Aerts TUL (1982) Pharmacokinetics of haloperidol decanoate: a 2-year followup. Int Pharmacopsychiatry 17: 238–246Google Scholar
  20. Tune LE, Creese I, Depaulo JR, Slavney PR, Coyle JT, Snyder SH (1980) Clinical state and serum neuroleptic levels measured by radioreceptor assay in schizophrenia. Am J Psychiatry 137: 187–190PubMedGoogle Scholar
  21. Van Putten T, Marder SR, May PRA, Poland RE, O’Brien RP (1985) Plasma levels of haloperidol and clinical response. Psychopharmacol Bull 21: 69–72PubMedGoogle Scholar
  22. Wilkins JN, Marder SR, van Putten T, Midha KK, Mintz J, Setoda D, May PRA (1987) Circulating prolactin predicts risk of exacerbation in patients on depot fluphenazine. Psychopharmacol Bull 23: 522–525Google Scholar
  23. Wistedt B, Jorgensen A, Wiles D (1982) A depot neuroleptic withdrawal study: plasma concentration of fluphenazine and flupenthixol and relapse frequency Psychopharmacology (Berlin) 78: 301–304CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1989

Authors and Affiliations

  • S. R. Marder
  • T. Van Putten
  • M. Aravagiri
    • 1
    • 2
  1. 1.Brentwood DivisionWest Los Angeles Veterans Administration Medical CenterLos AngelesUSA
  2. 2.Department of Psychiatry and Biobehavioral SciencesWest Los Angeles Veterans Administration Medical CenterLos AngelesUSA

Personalised recommendations